Teneligliptin

Drug Profile

Teneligliptin

Alternative Names: MP-513; Tenelia; teneligliptin hydrobromide hydrate

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Handok Inc; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Ketones; Piperazines; Pyrazoles; Thiazolidines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Tablet)
  • 16 Oct 2017 Handok completes the phase III TETRIS trial for Type-2 diabetes mellitus (Adjunctive therapy) in South Korea (NCT02567994)
  • 01 Jan 2017 Handok Pharmaceuticals plans a phase I drug-drug interaction trial in Healthy volunteers in South Korea (NCT03009513)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top